We can’t show the full text here under this license. Use the link below to read it at the source.
Associations of semaglutide with first‐time diagnosis of Alzheimer's disease in patients with type 2 diabetes: Target trial emulation using nationwide real‐world data in the US
Semaglutide use linked to first-time Alzheimer's diagnosis in people with type 2 diabetes in US real-world data
AI simplified
Abstract
Semaglutide was associated with a 40% to 70% reduced risk of first-time diagnosis in patients with type 2 diabetes mellitus compared to other antidiabetic medications.
- Semaglutide showed a of 0.33 for first-time Alzheimer's diagnosis compared to insulin.
- When compared to other GLP-1 receptor agonists, semaglutide had a hazard ratio of 0.59.
- The reduced risk associated with semaglutide was consistent across different obesity statuses, genders, and age groups.
- Patients taking semaglutide had significantly lower prescriptions for Alzheimer's-related medications.
AI simplified
Key numbers
0.33
for Diagnosis ( vs. insulin)
Compared to insulin in patients over 3 years.
0.59
for Diagnosis ( vs. other )
Compared to other in patients.
1,094,761
Patient Cohort Size
Total new users of antidiabetic medications in the study.